消瘤平移合剂抗肿瘤术后转移的临床观察

Clinical Study on Post-Operational Anti-Metastasis Effect of Xiaoliu Pingyi Mixture

目的 :观察消瘤平移合剂与化疗结合应用对肿瘤术后患者抗转移、复发及抑瘤方面的作用。方法 :96例常见肿瘤术后患者随机分为两组 ,观察组 ( 58例 )采用消瘤平移合剂加化疗 ,对照组 ( 38例 )单纯化疗 ,治疗 2个疗程后 ,观察两组近期 ( 1年 )远处转移、原位复发的情况 ;复发转移者继续治疗 2个月后 ,观察其病灶大小的变化 ,并观察治疗前后生活质量、体重、外周血细胞、免疫学、血液流变学指标变化。结果 :观察组远处转移率、局部复发率分别为 8 62 %、15 52 % ,显著低于对照组的 4 4 74 %、60 53% (P <0 0 1)。对于复发转移者其近期客观疗效 ,观察组有效率为 4 6 2 4 % ,对照组有效率为 2 4 0 0 % ,两组间差异有显著性(P <0 0 5)。消瘤平移合剂能够提高患者生活质量 ,调节T细胞亚群的失衡 ,改变血液流变性 ,并降低化疗的毒副作用。结论 :消瘤平移合剂配合化疗对常见肿瘤术后患者具有抑瘤、抗转移。

Objective: To observe the effect of combined use of chemotherapy (CT) and Xiaoliu Pingyi Mixture (XLPYM) in anti metastasis, anti relapse and tumor inhibition in patients after surgical operation. Methods: Ninety six patients of common tumor after operation were divided into 2 groups, the 58 patients in the observed group treated with CT plus XLPYM and the 38 patients in the control group treated with CT alone. After 2 courses of treatment, the status of 1 year remote metastasis and in local relapse of tumor were observed. For patients of relapse or metastasis, another 2 courses of treatment was given, then the changes of tumor size, quality of life, body weight, peripheral blood cells, immunity and hemorrheology were estimated and compared between the two groups. Results: The remote metastatic rate and local relapse rate in the observed group were lower than those in the control group significantly (8.62% vs 44.74% and 15.52% vs 60.53%, P<0 01). For patients of metastasis or relapse, the effective rate in the observed group was 46.24% and that in the control group was 24.00%, showing significant difference between the two groups (P<0 05). Clinical observation also displayed that XLPYM could elevate the quality of life, regulate the disordered T lymphocyte subsets, improve the hemorrheologic character and reduce the toxic adverse reaction of CT in patients. Conclusion: XLPYM in combining with CT has effects of tumor inhibition, anti metastasis and anti relapse in treating patients of common tumor in post operational period.